Johnson & Johnson (JNJ)
Johnson & Johnson (JNJ) Increases Yet Falls Behind Market: What Investors Need to Know
Johnson & Johnson (JNJ) closed at $241.3 in the latest trading session, marking a +1.21% move from the prior day.
Johnson & Johnson: Success In Multiple Myeloma Underpins $25B In Growth By 2030
Johnson & Johnson earns a Buy rating, driven by the FDA approval of its Tecvayli and Darzalex Faspro combination for R/R multiple myeloma, delivering best-in-class efficacy. This combination therapy achieved an 83.4% 36-month progression-free survival rate, significantly outperforming the control arm and expanding JNJ's addressable market. JNJ's oncology pipeline, especially in hematology, is positioned to offset Stelara's LOE, targeting $50B in oncology sales and $125B total revenue by 2030.
JNJ Q1 MedTech Preview: Key Drivers and China Headwinds to Watch
JNJ's MedTech unit rides cardiovascular strength and new product adoption, but China headwinds loom ahead of its Q1 earnings release.
Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Here's Why You Don't Bet Against This Dividend King
Markets have delivered plenty of twists lately, with inflation cooling but growth uneven and volatility still lurking around every earnings corner.
Johnson & Johnson: The Return Of The Dividend King
Johnson & Johnson is reiterated as a buy, driven by pipeline progress and recent valuation correction. Icotyde's early FDA approval and $8B peak sales potential could add 8% annual growth to JNJ's top line. Consensus projects JNJ EPS CAGR of 8.9% (2026–2030), with forward P/E compressing from 20.8x to 14.8x.
This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Royalty Pharma and J&J partner to develop autoimmune treatment
Royalty Pharma said on Monday it has signed a $500 million research and development agreement with Johnson & Johnson to advance an experimental antibody treatment for autoimmune diseases.
Procter & Gamble, Johnson & Johnson Among 9 Companies To Announce Dividend Increases In The First Half Of April
Procter & Gamble is set to announce its 70th consecutive year of dividend growth in April, joining an elite group of long-term dividend growers. I anticipate PG's dividend increase will be 3–5%, slightly below last year's 5% boost, yielding a forward yield of 3.05–3.11%. Investors were rewarded with 10%+ increases from 4 companies in March, including a 22% increase from insurance company Globe Life.
Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength
Johnson & Johnson shows relative strength with a bull flag breakout attempt, supported by key moving averages, signaling improving demand and potential upside toward higher Fibonacci extension targets.
Can New Drugs Drive J&J's Innovative Medicine Despite Stelara LOE?
JNJ's Innovative Medicine unit eyes Q1 growth on key drug momentum, but biosimilar pressure and Stelara's decline may weigh on results.
